BioCentury
ARTICLE | Finance

Chiasma's private decision

Why Chiasma and VCs opted for a $70M series E rather than an IPO

March 16, 2015 7:00 AM UTC

Chiasma Inc. profiles as a potential IPO candidate with a late-stage asset on the verge of registration. But MPM Capital's Todd Foley told BioCentury that the recent unexpected return of commercial rights for its octreotide acetate to treat acromegaly meant the timing wasn't right.

Instead, Chiasma's investors opted for an additional venture financing, putting in $70 million in an oversubscribed series E round led by an undisclosed crossover fund. New investors Rock Springs Capital and Sofinnova Ventures participated, along with existing investors MPM, F2 Capital, 7 Med Health Ventures, Abingworth and Arch Venture Partners. ...